Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and buparlisib

lapatinib has been researched along with buparlisib in 5 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(buparlisib)		Trials
(buparlisib)		Recent Studies (post-2010) (buparlisib)
1,9193051,44225648252

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)buparlisib (IC50)
Chain A, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoformHomo sapiens (human)0.262
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformRattus norvegicus (Norway rat)0.117
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.1363
Cytochrome P450 1A2Homo sapiens (human)0.011
Cytochrome P450 3A4Homo sapiens (human)0.027
Cytochrome P450 2C8Homo sapiens (human)0.04
Cytochrome P450 2B6Homo sapiens (human)0.011
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)0.0878
Cytochrome P450 2C19Homo sapiens (human)0.372
Aldo-keto reductase family 1 member C3Homo sapiens (human)8.7
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)0.055
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)0.2507
Serine/threonine-protein kinase mTORHomo sapiens (human)1.9814
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.5654
DNA-dependent protein kinase catalytic subunitHomo sapiens (human)6.917
Phosphatidylinositol 3-kinase catalytic subunit type 3Homo sapiens (human)2.4905
Phosphoinositide 3-kinase regulatory subunit 5Homo sapiens (human)0.129
Serine/threonine-protein kinase mTOR Mus musculus (house mouse)0.832
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformRattus norvegicus (Norway rat)0.523

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Arteaga, CL; Chanthaphaychith, S; Dahlman, K; Rexer, BN1
Liu, P; Xu, B; Zhang, C1
Autret, A; Bertucci, F; Boher, JM; Camerlo, J; Campone, M; Charafe-Jauffret, E; Extra, JM; Gonçalves, A; Guerin, M; Hervieu, A; Isambert, N; Lokiec, F; Pakradouni, J; Provansal, M; Rezai, K; Sabatier, R; Viens, P1

Trials

1 trial(s) available for lapatinib and buparlisib

ArticleYear
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; France; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2017

Other Studies

4 other study(ies) available for lapatinib and buparlisib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Breast cancer research : BCR, 2014, Jan-23, Volume: 16, Issue:1

    Topics: Aminopyridines; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Mice; Mice, Nude; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays

2014
Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:11

    Topics: Aminopyridines; Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lapatinib; Mice; Morpholines; ortho-Aminobenzoates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; PTEN Phosphohydrolase; Pyrimidinones; Quinazolines; Receptor, ErbB-2; Thiazoles; Xenograft Model Antitumor Assays

2016